Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance

Abstract

Funding information Dutch Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen; CBG-MEB)Aims: To evaluate the number and nature of reported congenital malformations (CMs) after intrauterine exposure to non-tumour necrosis factor inhibitor biologics (non-TNFi biologics) compared to certolizumab pegol (CZP).Methods: A retrospective comparative study was conducted in the EudraVigilance (EV) database. A safe biologic (CZP) was considered as the reference group. Odds ratios (ORs) for CMs were calculated for each non-TNFi biologic (including abatacept, anakinra, belimumab, ixekizumab, rituximab, secukinumab, tocilizumab, ustekinumab and vedolizumab), versus CZP (quantitative assessment). Then, CM patterns were reviewed in consultation with a clinical geneticist (qualitative assessment).Results: ORs were not statistically significant except for belimumab and vedolizumab (similar in magnitude). Except for vedolizumab, no specific CM patterns were observed for the included non-TNFi biologics. Three cases of corpus callosum agenesis (CCA) were identified for vedolizumab (versus none in CZP and other investigated non-TNFi biologics). Two of the CCA cases were associated with other neurological CMs (one cerebral ventriculomegaly with microcephaly and one polymicrogyria). This may indicate that these CCAs are related to undiagnosed genetic alterations or are associated with the underlying maternal disease, although a definite relationship with vedolizumab exposure cannot be ruled out. Conclusion: No special safety signal was identified regarding the occurrence of CMs after exposure to abatacept (n = 64), anakinra (n = 20), belimumab (n = 93), ixekizumab (n = 29), rituximab (n = 57), secukinumab (n = 128), tocilizumab (n = 124) and ustekinumab (n = 215). Regarding observed CCAs in the vedolizumab group (n = 113), no firm conclusions can be made based on available information.

Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms

“…Between the UST-treated and the control cohorts, differences among the variables included in the study were not observed [ 120 ]. Outcome data following maternal use of UST during pregnancy are becoming available from registries and prospective studies [ 122 , 123 , 124 , 125 , 126 , 127 ]. Based on these data, in the recent ECCO guidelines, the authors concluded that no increased risk of adverse pregnancy outcomes was identified with UST [ 2 , 126 , 127 , 128 ].…”

Considering belimumab during pregnancy: A more viable option over time

“…Ghalandari N, et al 24 performed a search in the EV database among pregnancy-related ADR reports (all reports until 11 March 2021). They compare the number and nature of congenital malformations (CMs) reported after intrauterine exposure to non-tumour necrosis factor inhibitor biologics, with certolizumab pegol (CZP) (chosen as the safest biologic in pregnancy).…”

Novel insights into the management of rheumatoid arthritis: one year in review 2023

“…A large retrospective analysis on healthcare databases including 3,564 RA patients and 14,256 age matched controls, showed a two-fold excess of pregnancy losses attributable to MTX use (OR 2. Additional safety data of nTNFi biologics comes from a pharmacovigilance analysis of mixed populations, including RA (87). No special safety signal was identified regarding the occurrence of congenital malformations after exposure to ABA (n=64), RTX (n=57), and TCZ (n=124).…”